THU0432 Apremilast, An Oral Phosphodiesterase 4 Inhibitor, Is Associated with Long-Term (104-Week) Improvement in Fatigue in Patients with Psoriatic Arthritis: Pooled Results from 3 Phase III, Randomized, Controlled Trials
Arthur Kavanaugh(University of California System), P. J. Mease(Providence College), Dafna D. Gladman(Toronto Western Hospital), Frédéric Lioté(Inserm), D. Nguyen, Georg Schett(Karolinska University Hospital), Christopher J Edwards(University Hospital Southampton NHS Foundation Trust), Airi Põder, Lichen Teng(Harbin Medical University), Paul Bird(UNSW Sydney)
Cited by 6
Related Papers
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update
|Annals of the Rheumatic Diseases|2020|2.8k
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update
|Annals of the Rheumatic Diseases|2022|1.9k
2022 update
|Radboud Repository (Radboud University)|2010|1.6k
Genome-wide scan reveals association of psoriasis with IL-23 and NF-κB pathways
|Nature Genetics|2009|1.4k
Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics
|Journal of the American Academy of Dermatology|2019|917